TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01683669

Intervention type: OTHER
Group type: OTHER
Intervention: Noisy-PSV 1
Description: Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.

Intervention type: OTHER
Group type: OTHER
Intervention: Noisy-PSV 2
Description: Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
Study: NCT02860949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL
Study: NCT01947920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl, 50 mg
Description: 50-mg overencapsulated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Size-matching capsules containing an appropriate inactive excipient
Study: NCT04194645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet
Study: NCT02860949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL
Study: NCT00978159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole 20 mg po for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Famotidine 40 mg po for 4 weeks
Study: NCT01844401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Spiromax®
Description: Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAir® HFA
Description: ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProAir® HFA
Description: ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Study: NCT03351504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solar lighting system
Description: consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
Study: NCT03398980

Intervention type: RADIATION
Intervention: survivors treated with CRT
Description: Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).

Intervention type: RADIATION
Intervention: survivors treated with CRT
Description: Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
Study: NCT03950661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Study: NCT04053699

Intervention type: DRUG
Intervention: Von Willebrand Factor-Containing Product
Description: Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
Study: NCT03656198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabivax-S
Description: Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water Injection
Description: The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
Study: NCT02056847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin calcium 4mg
Description: taking once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin calcium 2mg
Description: Taking once a day
Study: NCT03031509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Amniotic Epithelial Cells
Description: Human Amniotic Epithelial Cells transplant after debridement
Study: NCT03476161

Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.

Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
Study: NCT03075124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation
Description: A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
Study: NCT04475484

Intervention type: OTHER
Intervention: Online questionnaire
Description: Parents will receive a link to an online questionnaire through computing services of Lyon's Academy. They have to give their consent to allow their child to participate in the study. Then, children can complete the online questionnaire.~The questionnaire starts with few explanations on the context of the study, and ends with psycho-education advices and what to do in the event of psychological distress.
Study: NCT02994368

Intervention type: OTHER
Intervention: Observation

Intervention type: OTHER
Intervention: Observation
Study: NCT03031509

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: debridement
Description: debridement
Study: NCT01947920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Size-matching capsules containing an appropriate inactive excipient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Size-matching capsules containing an appropriate inactive excipient
Study: NCT03031509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement
Description: debridement
Study: NCT00797550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Repair Cells (BRCs)
Description: BRCs will be administered during spine fusion surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Study: NCT05474950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: minocycline capsule (100mg) per day orally
Study: NCT02614157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLND
Description: advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: labeled line
Study: NCT01335061

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nonacog alfa
Description: Period 1: During on-demand period, dosing at the discretion of investigator.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nonacog alfa
Description: Period 2: During the prophylaxis period, 100 IU/kg once weekly
Study: NCT02315118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-cell therapy + Rituximab + IL-2
Description: * T cells collection~* T cells expansion and modification in the laboratory~* T cells infusion back to the patients
Study: NCT00444743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MM-093
Description: 60 mg, administered subcutaneously, weekly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02022293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients in this group will take 20mg per night.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04130490

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Study: NCT04130490

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices

Intervention type: DEVICE
Intervention: ANTERION
Description: 3 repeat measurements performed with two of the ANTERION acquisition types and 3 repeat measurements performed with 2 acquisition types of the references devices
Study: NCT02086461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic pyloric dilatation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 15 mm pyloric balloon dilatation
Study: NCT04082598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum and Lactoferrin
Study: NCT01965990

Intervention type: OTHER
Intervention: NEP
Description: A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
Study: NCT01208506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
Study: NCT04194645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study: NCT04194645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 oral solution
Description: BI 474121 oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Placebo solution
Study: NCT01573299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization of stroke patients
Description: In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization of stroke patients
Description: In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset.
Study: NCT01208506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
Study: NCT02925039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehab with computer feedback
Description: Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT01208506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0000-0005
Description: A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.
Study: NCT01700231

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection of patient with neoplastic hepatic tumors
Study: NCT05019443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wedge Scoring Balloon
Description: Scoring balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon
Description: Conventional balloon
Study: NCT01611779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encore Tongue Suspension System
Description: The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
Study: NCT00940485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: 0.5mg po daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: 0.5mg po daily for 48 weeks
Study: NCT01208506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of NNC0114-0000-0005 placebo.
Study: NCT01402674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrupt cessation of phentermine pharmacotherapy
Description: Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
Study: NCT02965274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Fluoxetine Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warner Chilcott LLC's Sarafem Tablet
Study: NCT06029634

Intervention type: DIAGNOSTIC_TEST
Intervention: T-bet B cell
Description: The frequency, function, and phenotype of T-bet B cells was tested

Intervention type: DIAGNOSTIC_TEST
Intervention: T-bet B cell
Description: The frequency, function, and phenotype of T-bet B cells was tested

Intervention type: DIAGNOSTIC_TEST
Intervention: T-bet B cell
Description: The frequency, function, and phenotype of T-bet B cells was tested
Study: NCT00940485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc/week for 48 weeks
Study: NCT03826680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic laryngoscopy
Description: Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
Study: NCT05978635

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group A Standard 4 deep breaths measured in milliliters from the ventilator.
Description: Tidal volume breath measured in milliliters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group B Coached 4 deep breaths measured in milliliters from the ventilator
Description: Coached tidal volume breath measured in milliliters
Study: NCT01114360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
Study: NCT02940431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Autonomy
Description: Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Autonomy
Description: Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
Study: NCT01118975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1,250 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1,250 mg once daily
Study: NCT04514432

Intervention type: OTHER
Intervention: Music
Description: If patients experienced agitation, they were able to request to listen to music for 30 minutes. They listened to genre playlists generated by the music application Spotify.
Study: NCT01013662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glycemic control
Description: exogenous insulin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glycemic control
Description: exogenous insulin